Q1-10 worldwide Lipitor revenues of $2.76B were a tad higher than the $2.72B seen this time last year. However, MRK suffered an 11% drop in the sales of its once highly-touted Gardasil vaccine.
> However, MRK suffered an 11% drop in the sales of its once highly-touted Gardasil vaccine. What does that have to do with a PFE investment?
It has nothing to do with PFE. JNJ has been a dog for me but it has outperformed PFE consistantly for over 5 years now. Must be the Band-Aids.
good question. he sounds stupid, but what is behind his argument is "popular" in the circle of big pharma top layer.MRK failed to competing with GSK.considering Q1 is the best of 4 seasons for big pharmas. It is safe to say today is the 2010 prime of both companies.